Roth Capital initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Wednesday, April 11th, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price objective on the biotechnology company’s stock.
Shares of APVO stock opened at $4.31 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.14 and a quick ratio of 5.08. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.85.
In related news, insider Marvin L. White sold 100,000 shares of the company’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $2.93, for a total value of $293,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 15.60% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.